A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata. KIRKLAND, QC, December 4, 2023 – Today,… Read More
The Research Approval Processes Project (RAPP) is set to make improvements to the operational approval application process for research studies. Operational Approval, also known as an Operational Review, holds a… Read More
The innovative pharmaceutical industry commends the ambition to address climate change as an urgent health challenge at COP28, including through the agreement of the first ever Declaration on Climate and… Read More
Decision confirms the therapeutic value of Pemazyre® (pemigatinib) and need for new approaches to treat advanced cholangiocarcinoma (bile duct cancer) INESSS positive recommendation is an important milestone towards public funding for… Read More
VANCOUVER, BC — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold… Read More
